Xarelto Indications/Uses

2.5 mg: Rivaroxaban (Xarelto) is indicated for the prevention of cardiovascular death, myocardial infarction and stent thrombosis in patients after an acute coronary syndrome (ACS) (non-ST elevation or ST elevation myocardial infarction or unstable angina) in combination with acetylsalicylic acid (ASA) alone or with ASA plus thienopyridines clopidogrel or ticlopidine (see Dosage & Administration).
Rivaroxaban (Xarelto) is indicated for the prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) in combination with ASA (see Dosage & Administration).
10 mg: Rivaroxaban (Xarelto) is indicated for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.
Rivaroxaban (Xarelto) is indicated for the treatment of Deep Vein Thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE.
15 and 20 mg: Rivaroxaban (Xarelto) is indicated for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF).
Rivaroxaban (Xarelto) is indicated for the treatment of Deep Vein Thrombosis (DVT) and for the prevention of recurrent DVT and Pulmonary Embolism (PE).
Rivaroxaban (Xarelto) is indicated for the treatment of Pulmonary Embolism (PE) and for the prevention of recurrent PE and DVT.